---
title: "Rani Therapeutics: Buy Rating Reaffirmed on Strong Q3, Extended Cash Runway and RT-114 Catalyst; $5 Price Target Unchanged"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305056700.md"
description: "Canaccord Genuity analyst Edward Nash reaffirmed a Buy rating on Rani Therapeutics with an unchanged $5 price target. The decision cites strong Q3 performance, better-than-expected earnings, and an extended cash runway supporting operations through 2027. Additionally, upcoming Phase Ia data for the RT-114 candidate in late 2024 serves as a key catalyst."
datetime: "2026-11-10T18:26:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305056700.md)
  - [en](https://longbridge.com/en/news/305056700.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305056700.md)
generator: "portal-rs"
---

# Rani Therapeutics: Buy Rating Reaffirmed on Strong Q3, Extended Cash Runway and RT-114 Catalyst; $5 Price Target Unchanged

Edward Nash, an analyst from Canaccord Genuity, maintained the Buy rating on Rani Therapeutics Holdings. The associated price target remains the same with $5.00.

Edward Nash gave his rating based on several factors, including Rani Therapeutics’ better-than-expected third-quarter performance and improving financial visibility. The company posted a $0.04 per-share loss versus the $0.05 consensus estimate, while $53.4 million in cash and marketable securities is expected to support operations through at least the end of 2027. 

A major potential catalyst is upcoming Phase Ia pharmacokinetic data for RT-114, the company’s oral delivery candidate for a dual GLP-1/GIP therapy, expected by year-end. Progress toward a Phase Ib study could provide additional validation of the platform and its development prospects, supporting Nash’s Buy view and his unchanged 12-month price target of $5.

According to TipRanks, Nash is a 5-star analyst with an average return of 24.1% and a 49.26% success rate. Nash covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Cardiol Therapeutics, and Madrigal Pharmaceuticals.

### Related Stocks

- [RANI.US](https://longbridge.com/en/quote/RANI.US.md)
- [CRDL.US](https://longbridge.com/en/quote/CRDL.US.md)
- [MDGL.US](https://longbridge.com/en/quote/MDGL.US.md)
- [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md)

## Related News & Research

- [Rani Therapeutics management to join Chardan Healthcare Conference fireside chat](https://longbridge.com/en/news/301750750.md)
- [Selling Kingsway Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders](https://longbridge.com/en/news/306368572.md)
- [Nasdaq (NDAQ) Just Gave Investors Something To Think About](https://longbridge.com/en/news/306370324.md)
- [Rapid7 Lead Independent Director J. Benjamin Nye Sells 72% Of Holding](https://longbridge.com/en/news/306369615.md)
- [What Amgen Doubters Got Wrong](https://longbridge.com/en/news/306369302.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**